

審査の結果の要旨

氏名 チッタフーン ワノルラト

The present study aims to explore the potential mechanistic relationship of hyperinsulinemia, insulin resistance, and the elevation of PPAR γ underlying the development of hepatic steatosis, which is the essential component of metabolic dysfunction-associated fatty liver disease (MAFLD). The high-fat diet (HFD)-fed, *db/db*, and liver-specific insulin receptor substrate 1 and 2 knockout (LIRS1/2DKO) mice were prepared and analyzed. The following results were obtained.

1. In parallel to the development of hepatic steatosis, both HFD-fed and *db/db* mice exhibited excessive accumulation of hepatic cAMP. This was due to the insulin-induced repression of the cAMP transporter, multidrug resistance-associated protein 4 (MRP4).
2. The overaccumulation of cAMP levels led to the augmentation of PPAR γ mRNA levels in the liver, which was mediated by the endoplasmic reticulum (ER) stress-induced FoxO6 upregulation. Consequently, the triglyceride (TG) accumulation in the liver was increased. In contrast, the inhibition of ER stress or the ablation of FoxO6 substantially mitigated cAMP-induced PPAR γ upregulation, leading to the lowered hepatic TG concentration.
3. On the other hand, in mice-lacking hepatic insulin signaling (LIRS1/2DKO mice), which did not develop hepatic steatosis, the Mrp4-mediated cAMP extrusion remained intact. Additionally, the ER stress response was remarkably low in LIRS1/2DKO mice, coupled with decreased FoxO6 and PPAR γ expression levels.

Taken together, these results manifest that the overabundance of hepatic cAMP, caused by the reduction of MRP4, plays an indispensable role in the pathogenesis of hepatic steatosis under the hyperinsulinemic and insulin-resistant condition, whereby the steatohepatic mice displayed the unrestrained ER stress response, accompanied with increased expression levels of FoxO6 and PPAR γ . Therefore, approaches that enhance the MRP4-mediated cAMP egress in the liver could possibly serve as a novel therapeutic strategy for the treatment of hepatic steatosis, which would also provide the therapeutic benefits to MAFLD.

よって本論文は博士（医学）の学位請求論文として合格と認められる。